US FDA Staff Flags Concerns on MDMA-Assisted PTSD Treatment
Earlier today, staff from the U.S. health regulatory body expressed concerns regarding the interpretation of data from trials on the psychedelic drug MDMA for treating post-traumatic stress disorder (PTSD). These concerns emerged ahead of an upcoming meeting of the agency’s advisory panel. The comments have set the stage for in-depth discussions on the benefits and…
Allegations of Sexual Abuse in the Psychedelic Industry: How to Address and Prevent Misconduct
Sexual abuse during psychedelic treatments continues to be a major issue within the industry. Sexual misconduct does happen during psychedelic treatments, but it doesn’t often stay a secret for long. Though growing quickly, the industry is still small and exists in a bubble, so news of unethical behavior travels fast. Sexual misconduct in psychedelic treatment…
A Step in the Chaotic Journey Towards FDA-Approval of Psychedelic-Assisted Therapy
With only a few weeks left in the year, concern was rising over why MAPS PBC hadn’t yet submitted its NDA. All that, however, was put to rest yesterday when the Public Benefit Corporation announced that its submission to the FDA was officially complete. On December 12, 2023, the Multidisciplinary Association for Psychedelic Studies Public…
Psychedelic Conference Marks a Shift in the Strategy of the Industry
I arrived in Miami last Wednesday, ready for a few days of bright colors, passionate conversations, and mind-manifesting ideas. Psychedelic Week was in full swing, and I had a busy schedule consisting of panels, parties, and of course, the Wonderland Miami Conference. My goal for the week was simple: To gain new insights into the…